Selected article for: "acute respiratory infection and long study"
Author: Ansari, Sheeba; Memon, Mubeen; Kumar, Ratan; Memon, Sidra; Memon, Muhammad Khizar
Title: Do COVID-19 Antibodies Provide Long-Term Protection?
  • Cord-id: er2v7s95
  • Document date: 2021_1_3
    • ID: er2v7s95
    Snippet: Introduction: Post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, an immune response is generated among healthy, immunocompetent individuals with immunoglobulins (IgG and IgM) antibodies. IgM rises earlier than IgG, indicating a recent infection. However, a detailed analysis is required to assess long-term immune reactions induced by antibodies. Method and Materials: The study was conducted at a tertiary care hospital in Pakistan from June 2020 to October 2020 where seru
    Document: Introduction: Post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, an immune response is generated among healthy, immunocompetent individuals with immunoglobulins (IgG and IgM) antibodies. IgM rises earlier than IgG, indicating a recent infection. However, a detailed analysis is required to assess long-term immune reactions induced by antibodies. Method and Materials: The study was conducted at a tertiary care hospital in Pakistan from June 2020 to October 2020 where serum samples were collected from patients. The samples were obtained by phlebotomy for antibody testing. All the reactive patients were followed up after 60 days of initial testing. Results: A total of 728 patients participated in the study, of which 79​ (10.8%) were seropositive at baseline. Seventy-two (91.1%) participants came back for follow-up after 60 days (two months) and were included in the final analysis. Among the 72 participants, 35 (48.6%) exhibited symptoms of coronavirus disease 2019 (COVID-19) infection and 37 (51.4%) were asymptomatic. After 60 days, 37 (including 20 symptomatic and 17 asymptomatic) participants were still seropositive for SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) test. Mean change in percentage from seropositive to seronegative was more in asymptomatic compared to symptomatic patients (54.0% vs. 42.8%). Conclusion: In this study, humoral immunity against SARS-CoV-2 is not long-lasting among individuals with mild signs and symptoms. Care should be taken while implicating that antibodies can provide long term protection against SARS-CoV-2. Further large-scale studies are needed.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and long duration: 1, 2
    • absence presence and long term protection: 1, 2
    • absence presence and long term protective: 1
    • absence presence and longitudinal study: 1, 2, 3, 4, 5, 6
    • activity relationship and acute phase: 1
    • activity relationship and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity relationship and longitudinal study: 1, 2, 3
    • acute phase and long duration: 1, 2, 3, 4, 5, 6
    • acute phase and long term protection: 1, 2, 3
    • acute phase and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long last immunity: 1
    • acute respiratory syndrome and long term protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long term protective: 1, 2, 3, 4, 5, 6, 7, 8